NASDAQ:XNCR

Xencor Stock Forecast, Price & News

$37.29
+0.05 (+0.13 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$36.69
$37.61
50-Day Range
$36.45
$44.68
52-Week Range
$27.38
$58.35
Volume353,349 shs
Average Volume188,258 shs
Market Capitalization$2.17 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.65
30 days | 90 days | 365 days | Advanced Chart
Receive XNCR News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.


Xencor logo

About Xencor

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases in the United states and internationally. The company's product candidates include Obexelimab, an immune inhibitor that has completed Phase 2 clinical trial for the treatment of IgG4-related disease and systemic lupus erythematosus, as well as in Phase 1b/2a clinical trial to treat moderate-to-severe rheumatoid arthritis; Plamotamab, a tumor-targeted antibody, which is in Phase 1 clinical trial to treat non-Hodgkin lymphoma; XmAb717, XmAb841, and XmAb104, a bispecific antibody that is in Phase 1 clinical trial to treat patients with selected advanced solid tumors; and Vibecotamab, which is in Phase 1 clinical trial for the treatment of acute myeloid leukemia and other CD123-expressing hematologic malignancies. It is also developing Tidutamab that is in Phase 1 clinical trial to treat neuroendocrine tumors and gastrointestinal stromal tumors; XmAb564 to treat Autoimmune diseases; XmAb819 for the treatment of renal cell carcinoma; and XmAb306/RO7310729, which is in Phase 1 clinical trial to treat solid tumors. In addition, the company provides Monjuvi for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome; and AIMab7195 to reduce blood serum levels of IgE, which mediates allergic responses and allergic disease. It has a collaboration and license agreement with Genentech, MorphoSys AG, Nestlé S.A., Novartis AG, INmune Bio, Inc., Janssen Biotech, Inc., Astellas Pharma, Inc., Amgen Inc., Atreca, Inc., and The University of Texas MD Anderson Cancer Center. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.63 out of 5 stars

Medical Sector

403rd out of 2,099 stocks

Pharmaceutical Preparations Industry

192nd out of 831 stocks

Analyst Opinion: 3.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Xencor (NASDAQ:XNCR) Frequently Asked Questions

Is Xencor a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 1 sell rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Xencor stock.
View analyst ratings for Xencor
or view top-rated stocks.

What stocks does MarketBeat like better than Xencor?

Wall Street analysts have given Xencor a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Xencor wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Xencor's next earnings date?

Xencor is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Xencor
.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) announced its quarterly earnings data on Wednesday, May, 5th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.76) by $0.72. The biopharmaceutical company earned $33.97 million during the quarter, compared to analyst estimates of $13.05 million. Xencor had a negative net margin of 51.29% and a negative trailing twelve-month return on equity of 11.11%.
View Xencor's earnings history
.

How has Xencor's stock price been impacted by Coronavirus (COVID-19)?

Xencor's stock was trading at $28.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, XNCR shares have increased by 32.6% and is now trading at $37.29.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for XNCR?

8 Wall Street analysts have issued 12 month price objectives for Xencor's shares. Their forecasts range from $34.00 to $59.00. On average, they anticipate Xencor's share price to reach $51.13 in the next twelve months. This suggests a possible upside of 37.1% from the stock's current price.
View analysts' price targets for Xencor
or view top-rated stocks among Wall Street analysts.

Who are Xencor's key executives?

Xencor's management team includes the following people:
  • Dr. Bassil I. Dahiyat Ph.D., Co-Founder, CEO, Pres & Director (Age 51, Pay $886.43k)
  • Mr. John J. Kuch, Sr. VP & CFO (Age 62, Pay $545.51k)
  • Dr. John R. Desjarlais, Sr. VP of Research & Chief Scientific Officer (Age 57, Pay $599.29k)
  • Ms. Celia E. Eckert J.D., VP, Gen. Counsel & Corp. Sec. (Age 49, Pay $431.07k)
  • Dr. Allen S. Yang M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 53, Pay $199.38k)
  • Mr. Charles Liles, Associate Director and Head of Corp. Communications & Investor Relations
  • Ms. Julie Casciani, Exec. Director of HR

What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor CEO Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among Xencor's employees.

Who are some of Xencor's key competitors?

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Who are Xencor's major shareholders?

Xencor's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (16.33%), Price T Rowe Associates Inc. MD (9.79%), Primecap Management Co. CA (9.12%), EcoR1 Capital LLC (8.42%), Loomis Sayles & Co. L P (2.02%) and Geode Capital Management LLC (1.64%). Company insiders that own Xencor stock include Bassil I Dahiyat, Celia Eckert, John J Kuch, John R Desjarlais, John S Stafford III and Ronin Capital, Llc.
View institutional ownership trends for Xencor
.

Which major investors are selling Xencor stock?

XNCR stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Panagora Asset Management Inc., Los Angeles Capital Management LLC, Nuveen Asset Management LLC, Primecap Management Co. CA, Prudential Financial Inc., Credit Suisse AG, and Royal Bank of Canada. Company insiders that have sold Xencor company stock in the last year include Bassil I Dahiyat, Celia Eckert, and John J Kuch.
View insider buying and selling activity for Xencor
or view top insider-selling stocks.

Which major investors are buying Xencor stock?

XNCR stock was purchased by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, BlackRock Inc., Caas Capital Management LP, Squarepoint Ops LLC, Man Group plc, Dimensional Fund Advisors LP, Citigroup Inc., and Renaissance Technologies LLC.
View insider buying and selling activity for Xencor
or or view top insider-buying stocks.

How do I buy shares of Xencor?

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $37.29.

How much money does Xencor make?

Xencor has a market capitalization of $2.17 billion and generates $122.69 million in revenue each year. The biopharmaceutical company earns $-69,330,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis.

How many employees does Xencor have?

Xencor employs 202 workers across the globe.

What is Xencor's official website?

The official website for Xencor is www.xencor.com.

Where are Xencor's headquarters?

Xencor is headquartered at 111 WEST LEMON AVENUE, MONROVIA CA, 91016.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]


This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.